ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
PSA levels & TRT
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 156159" data-attributes="member: 3"><p><strong>Prostate Specific Antigen Levels during Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial</strong></p><p></p><p>Glenn R Cunningham, MD, Susan S Ellenberg, PhD, Shalender Bhasin, MD, Alvin M Matsumoto, MD, J Kellogg Parsons, MD, Peter Preston, MS, Jane A Cauley, DrPH, Thomas M Gill, MD, Ronald S Swerdloff, MD, Christina Wang, MD </p><p></p><p>The Journal of Clinical Endocrinology & Metabolism, jc.2019-00806,</p><p></p><p></p><p>Abstract</p><p>Context</p><p>Prostate specific antigen (PSA) changes during testosterone treatment of older hypogonadal men have not been rigorously evaluated. The Endocrine Society Guidelines recommendation of urological referral for a confirmed increase in PSA >1.4 ng/mL is not based on PSA changes in testosterone-treated men.</p><p></p><p>Design</p><p>Double-blinded, placebo-controlled trial.</p><p></p><p>Setting</p><p>Twelve United States academic medical centers.</p><p></p><p>Participants</p><p>790 hypogonadal men ≥65 years with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded.</p><p></p><p>Interventions</p><p>Testosterone or placebo gel for 12 months.</p><p></p><p>Main outcomes</p><p>Percentile changes in PSA during testosterone treatment for 12 months.</p><p></p><p>Results</p><p>Testosterone treatment that increased testosterone levels from 232 ± 63 ng/dL to mid-normal was associated with a small but significantly greater increase (p<0.001) in PSA levels than placebo treatment. Serum PSA levels increased from 1.14±0.86 ng/mL (mean ±SD) at baseline by 0.47±1.1 ng/mL at 12 months in the testosterone group and from 1.25±0.86 ng/mL by 0.06±0.72 ng/mL in the placebo group. Five percent of men treated with testosterone had an increase ≥1.7 ng/mL and 2.5% of men had an increase of ≥3.4 ng/mL. A confirmed absolute PSA >4.0 ng/mL at 12 months was observed in 1.9% of men in the testosterone group and 0.3% in the placebo group. Four men were diagnosed with prostate cancer; two were Gleason 8.</p><p></p><p>Conclusions</p><p>When hypogonadal, older men with normal baseline PSA are treated with testosterone, 5% had an increase in PSA ≥1.7 ng/mL, and 2.5% had an increase ≥3.4 ng/mL.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 156159, member: 3"] [B]Prostate Specific Antigen Levels during Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial[/B] Glenn R Cunningham, MD, Susan S Ellenberg, PhD, Shalender Bhasin, MD, Alvin M Matsumoto, MD, J Kellogg Parsons, MD, Peter Preston, MS, Jane A Cauley, DrPH, Thomas M Gill, MD, Ronald S Swerdloff, MD, Christina Wang, MD The Journal of Clinical Endocrinology & Metabolism, jc.2019-00806, Abstract Context Prostate specific antigen (PSA) changes during testosterone treatment of older hypogonadal men have not been rigorously evaluated. The Endocrine Society Guidelines recommendation of urological referral for a confirmed increase in PSA >1.4 ng/mL is not based on PSA changes in testosterone-treated men. Design Double-blinded, placebo-controlled trial. Setting Twelve United States academic medical centers. Participants 790 hypogonadal men ≥65 years with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded. Interventions Testosterone or placebo gel for 12 months. Main outcomes Percentile changes in PSA during testosterone treatment for 12 months. Results Testosterone treatment that increased testosterone levels from 232 ± 63 ng/dL to mid-normal was associated with a small but significantly greater increase (p<0.001) in PSA levels than placebo treatment. Serum PSA levels increased from 1.14±0.86 ng/mL (mean ±SD) at baseline by 0.47±1.1 ng/mL at 12 months in the testosterone group and from 1.25±0.86 ng/mL by 0.06±0.72 ng/mL in the placebo group. Five percent of men treated with testosterone had an increase ≥1.7 ng/mL and 2.5% of men had an increase of ≥3.4 ng/mL. A confirmed absolute PSA >4.0 ng/mL at 12 months was observed in 1.9% of men in the testosterone group and 0.3% in the placebo group. Four men were diagnosed with prostate cancer; two were Gleason 8. Conclusions When hypogonadal, older men with normal baseline PSA are treated with testosterone, 5% had an increase in PSA ≥1.7 ng/mL, and 2.5% had an increase ≥3.4 ng/mL. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
PSA levels & TRT
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top